<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113735</url>
  </required_header>
  <id_info>
    <org_study_id>QSC01-ARDS-01</org_study_id>
    <nct_id>NCT02113735</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Acthar in Subjects With ARDS</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of H.P. Acthar® Gel (Acthar) in Subjects With Acute Respiratory Distress Syndrome (ARDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being performed to evaluate the potential efficacy and safety of Acthar as a&#xD;
      treatment for moderate-severe Acute Respiratory Distress Syndrome (ARDS). Approximately 210&#xD;
      subjects will be randomized to 1 of 6 possible treatment groups in a 3:2:3:2:3:2 ratio. Study&#xD;
      medication (SM) will be administered via subcutaneous (SC) injection for 4 weeks using a&#xD;
      blinded gradually tapering regimen, and subjects will be followed for 60 days&#xD;
      post-randomization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    A company decision was made not to proceed with the study.&#xD;
  </why_stopped>
  <start_date type="Anticipated">August 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ventilator-free days (subjects alive and breathing without assistance for ≥ 48 hr) by Day 28 after randomization</measure>
    <time_frame>60 days (28 days of treatment with a 32 day follow-up period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at Day 28 and Day 60</measure>
    <time_frame>60 days (28 days of treatment with a 32 day follow-up period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU-free and hospital free days for all subjects who survive to ICU and hospital discharge, respectively</measure>
    <time_frame>60 days (28 days of treatment with a 32 day follow-up period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of extra-pulmonary organ failure-free days</measure>
    <time_frame>60 days (28 days of treatment with a 32 day follow-up period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PaO2/FiO2 ratio and oxygenation index (OI) from baseline for subjects on mechanical ventilation</measure>
    <time_frame>60 days (28 days of treatment with a 32 day follow-up period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic Organ Failure Assessment Score (SOFA) score from baseline.</measure>
    <time_frame>60 days (28 days of treatment with a 32 day follow-up period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent serious adverse events</measure>
    <time_frame>60 days (28 days of treatment with a 32 day follow-up period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number, severity and site of new infections developing at least 48 hr after initiation of Study Medication</measure>
    <time_frame>60 days (28 days of treatment with a 32 day follow-up period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who discontinue treatment because of serious safety concerns</measure>
    <time_frame>60 days (28 days of treatment with a 32 day follow-up period)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H.P. Acthar® Gel , 64 U, 0.8 mL daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 0.8 mL, daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H.P. Acthar® Gel , 32 U, 0.4 mL, 2x daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 0.4 mL, 2x daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H.P. Acthar® Gel , 16 U, 0.2 mL, 2x daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 0.2 mL, 2x daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H.P. Acthar® Gel (repository corticotropin injection)</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <other_name>Acthar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients ≥ 18 years.&#xD;
&#xD;
          2. ARDS as defined by:&#xD;
&#xD;
               -  PaO2 /FiO2 ≤ 200 mmHg with PEEP ≥ 5cm H2O.&#xD;
&#xD;
               -  Bilateral opacities on chest radiography not explained by atelectasis, effusions,&#xD;
                  nodules, or preexisting disease.&#xD;
&#xD;
               -  Requirement for positive pressure ventilation via an endotracheal tube.&#xD;
&#xD;
               -  Respiratory failure not fully explained by cardiac failure or fluid overload. If&#xD;
                  no identifiable risk factor for ARDS is identified, left atrial hypertension must&#xD;
                  be excluded by objective measures (e.g. transthoracic echocardiogram).&#xD;
&#xD;
               -  Criteria 2a, 2b, and 2c must occur within the same 24 hr period.&#xD;
&#xD;
          3. Enrollment between 24 hours and 10 days after ARDS criteria are met.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject unwilling to receive or intolerant of SC injections.&#xD;
&#xD;
          2. Subject, surrogate, or physician not committed to full supportive care. A &quot;Do Not&#xD;
             Resuscitate&quot; (DNR) order alone without other limitations of care does not require&#xD;
             study exclusion.&#xD;
&#xD;
          3. Moribund subject with death perceived to be imminent. For the purposes of this study,&#xD;
             moribund is defined by a requirement for ≥ 2 high dose vasopressors AND acute organ&#xD;
             failures in ≥ 3 organs for ≥ 24 hours prior to study entry.&#xD;
&#xD;
          4. Home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for&#xD;
             continuous positive airway pressure or bi-level positive airway pressure (CPAP/BIPAP)&#xD;
             used solely for sleep-disordered breathing prior to onset of ARDS.&#xD;
&#xD;
          5. Known contraindication to Acthar per package insert Section 4 (Appendix C):&#xD;
             scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent&#xD;
             surgery, history of or the presence of peptic ulcer, congestive heart failure,&#xD;
             uncontrolled hypertension, primary adrenocortical insufficiency, or adrenal cortical&#xD;
             hyperfunction.&#xD;
&#xD;
          6. Gastrointestinal/Hepatic: History of chronic active hepatitis, active Hepatitis B or&#xD;
             acute or chronic Hepatitis C infection, OR moderate-severe chronic liver disease as&#xD;
             defined by a Child-Pugh Score &gt;&#xD;
             11(http://gihep.com/calculators/hepatology/child-pugh-score/), OR any evidence of&#xD;
             hemodynamically significant active gastrointestinal (GI) bleeding.&#xD;
&#xD;
          7. Any subject with signs or symptoms concerning for an active infection that has not&#xD;
             been treated for &gt; 48 hours prior to randomization with either empiric broad-spectrum&#xD;
             or pathogen-directed anti-microbial therapy.&#xD;
&#xD;
          8. Immune System: Known immune-compromised status, including but not limited to&#xD;
             individuals who have undergone organ transplantation or who are known to be positive&#xD;
             for the human immunodeficiency virus (HIV).&#xD;
&#xD;
          9. Burns &gt;20% total body surface area, or any burn injury accompanied by smoke&#xD;
             inhalational injury.&#xD;
&#xD;
         10. Major surgery within 48 hours before randomization, OR evidence of currently active&#xD;
             bleeding postoperatively, OR plan for any major surgery during the study period.&#xD;
&#xD;
         11. Administration of any other investigational drug or participation in an interventional&#xD;
             clinical research study for ARDS within 30 days of planned randomization or during the&#xD;
             60 day study duration.&#xD;
&#xD;
         12. Presence of any other clinically significant disease or disorder (including those&#xD;
             listed in Appendix C package insert Section 5 [Warnings and Precautions]) which, in&#xD;
             the opinion of the Investigator (by its nature or by being inadequately controlled),&#xD;
             might put the subject at risk due to participation in the study, or may influence the&#xD;
             results of the study or the subject's ability to complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>Acthar</keyword>
  <keyword>ACTH</keyword>
  <keyword>H.P. Acthar Gel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

